1 Min Read
April 27 (Reuters) - Sage Therapeutics Inc:
* Sage Therapeutics - initiated phase 1 single ascending dose (SAD) trial of sage-718; top-line results from sad study are expected in 2H of 2017 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.